Mepolizumab proved efficacious for eosinophilic granulomatosis with polyangiitis (EGPA, former Churg-Strauss) at the dosage of 300mg/4 weeks in the randomized controlled MIRRA trial. Few successful real-life experiences with the dosage approved for severe eosinophilic asthma (100mg/4 weeks) were recently reported. We retrospectively assessed the effectiveness and safety of mepolizumab 100 and 300mg/4 weeks in a large European EGPA cohort.
Bettiol, A., Urban, M.L., Dagna, L., Cottin, V., Franceschini, F., Del Giacco, S., et al. (2022). Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study. ARTHRITIS & RHEUMATOLOGY, 74(2), 295-306 [10.1002/art.41943].
Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study
Bargagli, Elena;
2022-01-01
Abstract
Mepolizumab proved efficacious for eosinophilic granulomatosis with polyangiitis (EGPA, former Churg-Strauss) at the dosage of 300mg/4 weeks in the randomized controlled MIRRA trial. Few successful real-life experiences with the dosage approved for severe eosinophilic asthma (100mg/4 weeks) were recently reported. We retrospectively assessed the effectiveness and safety of mepolizumab 100 and 300mg/4 weeks in a large European EGPA cohort.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Mepolizumab for Eosinophilic Granulomatosis- Bettiol-2021.pdf
accesso aperto
Descrizione: articolo
Tipologia:
PDF editoriale
Licenza:
Creative commons
Dimensione
704.1 kB
Formato
Adobe PDF
|
704.1 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
https://hdl.handle.net/11365/1151441